Enlivex Ltd. (ENLV)
1.82
-0.72
(-28.35%)
USD |
NASDAQ |
Oct 30, 14:34
Enlivex EPS Diluted (Quarterly) : 97.84 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 97.84 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 386.85 |
| September 30, 2025 | -1.376 |
| June 30, 2025 | -1.174 |
| March 31, 2025 | -2.179 |
| December 31, 2024 | -3.283 |
| September 30, 2024 | -1.834 |
| June 30, 2024 | -2.376 |
| March 31, 2024 | -3.316 |
| December 31, 2023 | -7.335 |
| September 30, 2023 | -4.810 |
| June 30, 2023 | -5.482 |
| March 31, 2023 | -5.847 |
| December 31, 2022 | -5.854 |
| September 30, 2022 | -4.676 |
| June 30, 2022 | -8.092 |
| March 31, 2022 | -6.716 |
| December 31, 2021 | -3.875 |
| September 30, 2021 | -2.805 |
| June 30, 2021 | -2.547 |
| March 31, 2021 | -2.913 |
| December 31, 2020 | -6.467 |
| September 30, 2020 | -2.367 |
| June 30, 2020 | -3.394 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.045 |
| December 31, 2019 | -4.161 |
| September 30, 2019 | -3.514 |
| June 30, 2019 | -2.168 |
| March 31, 2019 | -10.34 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | -20.40 |
| September 30, 2017 | -38.40 |
| June 30, 2017 | -60.00 |
| March 31, 2017 | -96.00 |
| December 31, 2016 | -114.00 |
| September 30, 2016 | -168.00 |
| June 30, 2016 | -132.00 |
| March 31, 2016 | -192.00 |
| December 31, 2015 | -204.00 |
| September 30, 2015 | -150.00 |
| June 30, 2015 | -156.00 |
| March 31, 2015 | -138.00 |
| December 31, 2014 | -132.00 |
| September 30, 2014 | -96.00 |
| June 30, 2014 | -60.00 |
| March 31, 2014 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Polyrizon Ltd. | -- |
| NovelStem International Corp. | -0.0017 |
| Brainstorm Cell Therapeutics, Inc. | -0.3494 |
| Summit Therapeutics, Inc. | -0.2772 |
| PeptiDream Inc. | -0.0559 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.892B |
| Total Expenses (Quarterly) | -1.892B |
| Enterprise Value | 54.67M |
| Earnings Yield | 26.56K% |